PARADIGM-HF Study

The PARADIGM-HF study was a large clinical trial that tested whether a medication called angiotensin receptor-neprilysin inhibitor (ARNI) improves outcomes for people with heart failure with reduced ejection fraction (HFrEF). It compared this new drug to the standard treatment (ACE inhibitors) and found that ARNI significantly lowered the risk of death and hospitalization from heart failure. The study demonstrated that ARNI could be a better option for managing this condition, improving both survival and quality of life for patients with weakened heart function.